Literature DB >> 23823741

Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia.

Taro Kishi1, Nakao Iwata1.   

Abstract

We examined whether noradrenergic and specific serotonergic antidepressants (NaSSAs: mirtazapine and mianserin), as augmentation therapy, have therapeutic potential for schizophrenia treatment. A systematic review was conducted of PubMed, Cochrane Library and PsycINFO in December 2012 and meta-analyses of double-blind, randomized placebo-controlled trials were performed. Standardized mean difference (SMD), risk ratio (RR), number-needed-to-treat (NNT), number-needed-to-harm (NNH) and 95% confidence intervals (CI) were calculated. Results were across 12 studies and 362 patients were included (mirtazapine: seven trials and 221 patients; mianserin: five trials and 141 patients). NaSSA augmentation therapy was superior to placebo in overall symptoms (S.M.D. = -0.75, CI -1.24 to -0.26, p = 0.003, N = 11, n = 301), negative symptoms (S.M.D. = -0.88, CI -1.41 to -0.34, p = 0.001, N = 9, n = 240) and response rate (RR = 0.71, CI 0.57-0.88, p = 0.002, NNT = 4, p<0.00001, N = 6, n = 163). There was no significant difference in positive symptoms, depressive symptoms or discontinuation rate between NaSSAs and placebo treatments. In addition, no patients who received NaSSAs developed worsening psychosis during the study. For individual NaSSAs, mirtazapine was superior to placebo in overall symptoms (S.M.D. = 0.98, CI = -1.74 to -0.22, p = 0.01, N = 7, n = 194), negative symptoms (S.M.D. = -1.25, CI -1.88 to -0.62, p = 0.0001, N = 6, n = 172) and response rate (RR = 0.70, p = 0.04, NNT = 4, p = 0.0004, N = 4, n = 119). Moreover, NaSSAs were associated with reduced akathisia score (p < 0.00001) and extrapyramidal symptom scales (p = 0.01). However, NaSSAs caused drowsiness/sedation/somnolence compared with placebo (RR = 3.52, p = 0.002, NNT = 6, p = 0.01, N = 8, n = 209). Our results indicate that NaSSA (especially mirtazapine) augmentation therapy improved overall and negative symptoms in patients with schizophrenia. Because the included studies were small, the results should be treated with caution.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23823741     DOI: 10.1017/S1461145713000667

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  8 in total

Review 1.  Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.

Authors:  Selene R T Veerman; Peter F J Schulte; Lieuwe de Haan
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

Review 2.  Anxiety in Patients with Schizophrenia: Epidemiology and Management.

Authors:  Henk Temmingh; Dan J Stein
Journal:  CNS Drugs       Date:  2015       Impact factor: 5.749

Review 3.  Pharmacological treatment of negative symptoms in schizophrenia.

Authors:  Hans-Jürgen Möller; Pal Czobor
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-04-21       Impact factor: 5.270

Review 4.  Selective noradrenaline reuptake inhibitors for schizophrenia.

Authors:  Paul R L Matthews; Jamie Horder; Michael Pearce
Journal:  Cochrane Database Syst Rev       Date:  2018-01-25

Review 5.  Augmentation with antidepressants in schizophrenia treatment: benefit or risk.

Authors:  Ye-Meng Mao; Ming-Dao Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-16       Impact factor: 2.570

6.  Schizophrenia, Depressive Symptoms, and Antipsychotic Drug Treatment.

Authors:  Gavin P Reynolds; Olga O McGowan
Journal:  Int J Neuropsychopharmacol       Date:  2021-04-21       Impact factor: 5.176

7.  Metacognition-augmented cognitive remediation training reduces jumping to conclusions and overconfidence but not neurocognitive deficits in psychosis.

Authors:  Steffen Moritz; Teresa Thoering; Simone Kühn; Bastian Willenborg; Stefan Westermann; Matthias Nagel
Journal:  Front Psychol       Date:  2015-08-03

8.  Comparison of Metabolite Concentrations in the Left Dorsolateral Prefrontal Cortex, the Left Frontal White Matter, and the Left Hippocampus in Patients in Stable Schizophrenia Treated with Antipsychotics with or without Antidepressants. ¹H-NMR Spectroscopy Study.

Authors:  Dominik Strzelecki; Piotr Grzelak; Michał Podgórski; Olga Kałużyńska; Ludomir Stefańczyk; Magdalena Kotlicka-Antczak; Agnieszka Gmitrowicz
Journal:  Int J Mol Sci       Date:  2015-10-15       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.